

	論文名	著者	共著	発表雑誌名	巻 vol(No)	ページ e13241	掲載年
1	Effect of mirabegron on tight junction molecules in primary cultured rat Sertoli cells.	Tanaka M	Chiba K, Okada K, Fujisawa M	Andrologia	51(5)		2019年
2	Editorial Comment to Updates in endourological management of urolithiasis.	Shigemura K	Fujisawa M	Int J Urol.	26	183–184	2019年
3	Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan	Harada K	Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H	Int J Urol.	26	202–210	2019年
4	External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib	Okamura Y	Hinata N, Terakawa T, Furukawa J, Harada K, Nakano Y, Nakamura I, Inoue T, Ogawa T, Fujisawa M	Int J Clin Oncol	24(6)	698–705	2019年
5	Efficacy of Prophylactic Antimicrobial Administration of Tazobactam/Piperacillin for Radical Cystectomy with Urinary Diversion: A Multicenter Study.	Shigemura K	Tanaka K, Hamasuna R, Ishikawa K, Matsumoto T, Arakawa S, Kiyota H, Yamamoto S, Fujisawa M	Urol Int.	102(3)	293–298	2019年
6	Total necrosis after sequential treatment with pazopanib followed by nivolumab in a patient with renal cell carcinoma involving the inferior vena cava.	Shiraishi Y	Terakawa T, Jimbo N, Shigemura K, Hinata N, Fujisawa M	Int J Urol.	26(2)	313–314	2019年
7	Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis.	Okamura Y	Terakawa T, Sakamoto M, Bando Y, Suzuki K, Hara T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M	In Vivo	33	2013–2019	2019年
8	Protocol for a comparison study of 1-day (single dose) versus 2-day prophylactic antibiotic administration in Holmium Laser enucleation of the prostate (HoLEP): a randomized controlled trial.	Shigemura K	Yamamichi F, Nishimoto K, Kitagawa K, Fujisawa M	F1000Res	8	161	2019年
9	Effect of Preoperative Dutasteride on Holmium Laser Enucleation of the Prostate.	Shigemura K	Kitagawa K, Chen KC, Sung SY, Fujisawa M	Urol Int	4	1–5	2019年
10	Editorial Comment to Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.	Shigemura K	Fujisawa M	Int J Urol.	26(10)	954–955	2019年
11	Comment for "nomogram establishment for surgery-related complications in partial nephrectomy".	Shigemura K	Sung SY, Chen KC, Fujisawa M	Ann Transl Med.	7(Suppl 3)	S120	2019年
12	Editorial Comment to Potential of hyperbaric oxygen in urological diseases.	Shigemura K	Fujisawa M.	Int J Urol.	26(9)	867	2019年
13	Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer	Suzuki K	Terakawa T, Shigemura K, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M	MOLECULAR AND CLINICAL ONCOLOGY	11	523–530	2019年
14	Directed differentiation of human induced pluripotent stem cells into mature stratified bladder urothelium	Suzuki K	Koyanagi-Aoi M, Uehara K, Hinata N, Fujisawa M, Aoi T	Scientific Reports	9	10506	2019年
15	Recovery of Spermatogenesis Following Cancer Treatment With Cytotoxic Chemotherapy and Radiotherapy	Okada K	Fujisawa M	World J Mens Health	37	166–174	2019年
16	Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model	Hara T	Miyake H, Hinata N, Fujisawa M	Anticancer Res.	39(9)	4737–4742	2019年
17	Trifecta' outcomes of robot-assisted partial nephrectomy: a large Japanese multicenter study.	Furukawa J	Kanayama H, Azuma H, Inoue K, Kobayashi Y, Kashiwagi A, Segawa T, Takahashi Y, Horie S, Ogawa O, Takenaka A, Shiroki R, Tanabe K, Fujisawa M	Int J Clin Oncol.	25	347–353	2019年

A Prospective, Open-Label, Interventional Study
Protocol to Evaluate Treatment Efficacy of Nivolumab
18 Based on Serum-Soluble PD-L1 Concentration for
Patients With Metastatic and Unresectable Renal
Cell Carcinoma

Bando Y

**Hinata N, Omori T, Fujisawa
M**

BMJ Open

10

12

2019年